MIRA Pharmaceuticals (NASDAQ:MIRA) | WebDisclosure

Basculer en Français

9477	Companies
185475	Keywords
117817	Articles
99317	Press releases

Home
Companies
MIRA Pharmaceuticals

PRESS RELEASE

published on 05/08/2025 at 14:00, 6 months 28 days ago

MIRA Pharmaceuticals Announces Board Approval of SKNY Acquisition Reflecting $60+ Million in Combined Enterprise Value Based on Independent Review
MIRA Pharmaceuticals, Inc. announces board approval for strategic acquisition of SKNY Pharmaceuticals targeting obesity and nicotine dependence. $5 million contribution from SKNY. Merger subject to shareholder approval

Acquisition Obesity MIRA Pharmaceuticals SKNY Pharmaceuticals Nicotine Dependence
BRIEF

published on 05/06/2025 at 14:05, 6 months 30 days ago

MIRA Pharmaceuticals Announces Absence of Neurotoxicity in Ketamir-2 Study

Phase I Trial MIRA Pharmaceuticals Ketamir-2 NMDA Receptor Neurotoxicity Study
BRIEF

published on 05/06/2025 at 14:05, 6 months 30 days ago

MIRA Pharmaceuticals annonce l'absence de neurotoxicité dans l'étude Ketamir-2

Essai De Phase I MIRA Pharmaceuticals Ketamir-2 Récepteur NMDA Étude De Neurotoxicité
PRESS RELEASE

published on 05/06/2025 at 14:00, 6 months 30 days ago

MIRA Pharmaceuticals Reports No Brain Toxicity in FDA-Required Study of Ketamir-2, Confirming Absence of Ketamine-Linked Neurotoxicity
MIRA Pharmaceuticals announces positive preclinical results for oral NMDA receptor antagonist Ketamir-2, showing no brain toxicity. Phase I clinical trial ongoing

Phase I Clinical Trial Preclinical Results MIRA Pharmaceuticals Ketamir-2 Oral NMDA Receptor Antagonist
BRIEF

published on 04/23/2025 at 14:05, 7 months 12 days ago

MIRA Pharmaceuticals Announces Promising Results for Ketamir-2 Topical Formulation

FDA Fast Track Ketamir-2 Topical Formulation In Vitro Testing Pain Relief Market
BRIEF

published on 04/23/2025 at 14:05, 7 months 12 days ago

MIRA Pharmaceuticals annonce des résultats prometteurs pour la formulation topique du kétamir-2

Procédure Accélérée De La FDA Ketamir-2 Formulation Topique Tests In Vitro Marché Du Soulagement De La Douleur
PRESS RELEASE

published on 04/23/2025 at 14:00, 7 months 12 days ago

MIRA Pharmaceuticals Reports Positive In Vitro Drug Release Data for Topical Ketamir-2, Targeting $11B+ U.S. Topical Pain Relief Market and Exploring FDA Fast Track Designation
MIRA Pharmaceuticals announces completion of IVRT for topical Ketamir-2 formulation in pain-related conditions, aiming to address market needs and regulatory considerations

MIRA Pharmaceuticals Neuropathic Pain Topical Formulation IVRT FDA Guidance
BRIEF

published on 04/16/2025 at 14:05, 7 months 19 days ago

MIRA Pharmaceuticals Reports Promising Ketamir-2 Data for Diabetic Neuropathy

Clinical Trials MIRA Pharmaceuticals Ketamir-2 Diabetic Neuropathy Non-Opioid Treatments
BRIEF

published on 04/16/2025 at 14:05, 7 months 19 days ago

MIRA Pharmaceuticals publie des données prometteuses sur le kétamir-2 pour la neuropathie diabétique

Essais Cliniques MIRA Pharmaceuticals Ketamir-2 Neuropathie Diabétique Traitements Non Opioïdes
PRESS RELEASE

published on 04/16/2025 at 14:00, 7 months 19 days ago

MIRA Pharmaceuticals Announces Positive Results for Ketamir-2 in Diabetic Neuropathy Animal Model, Reinforcing Confidence Ahead of Phase I Completion
MIRA Pharmaceuticals announces strong efficacy of Ketamir-2 in diabetic neuropathy model, offering potential breakthrough treatment for patients. Phase IIa trial planned

Clinical Trial MIRA Pharmaceuticals Ketamir-2 Neuropathic Pain Diabetic Neuropathy

Accesswire

Published on 12/05/2025 at 14:00, 1 hour 3 minutes ago

Ocean Power Technologies Attending the 3rd Annual DealFlow Discovery Conference
Published on 12/05/2025 at 14:00, 1 hour 3 minutes ago

Bonk, Inc. Highlights Major Ecosystem Milestone: Launch of Regulated BONK ETP on SIX Swiss Exchange
Published on 12/05/2025 at 02:35, 12 hours 28 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 12 hours 33 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 14 hours 3 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 14:22, 41 minutes ago

EQS-Adhoc: Jungheinrich AG: Jungheinrich expects to complete sale of its Russian subsidiary in 2026 and adjusts forecast for the 2025 financial year
Published on 12/05/2025 at 14:16, 46 minutes ago

Advanced Blockchain AG: Successful Completion of Token Generation Event of Portfolio company Talisman
Published on 12/05/2025 at 14:10, 53 minutes ago

The Kingdom of Saudi Arabia Launches a New Official Platform, "Saudi Properties", Ahead of the Non-Saudi Property Ownership Law
Published on 12/05/2025 at 13:45, 1 hour 18 minutes ago

BingX Introduces Recurring Buy to Help Users Ride Out Crypto Market Swings
Published on 12/05/2025 at 13:00, 2 hours 3 minutes ago

Zentra Group plc: Posting of Notice of Annual General Meeting

Les Echos

Published on 12/05/2025 at 13:58, 1 hour 5 minutes ago

RELATIF A LA MISE A DISPOSITION DU PUBLIC DE LA NOTE D'INFORMATION ET DES INFORMATIONS RELATIVES AUX CARACTERISTIQUES, NOTAMMENT JURIDIQUES, FINANCIERES ET COMPTABLES DE LEGRAND FRANCE
Published on 12/05/2025 at 08:45, 6 hours 18 minutes ago

Air Liquide va étendre et électrifier son unité de production d'oxygène à Shaanxi, soutenant ainsi l'engagement de la Chine à décarboner son industrie
Published on 12/05/2025 at 08:45, 6 hours 18 minutes ago

Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/05/2025 at 08:42, 6 hours 21 minutes ago

ENGIE - déclaration mensuelle du nombre total d'actions et de droits de vote composant le capital au 30 novembre 2025
Published on 12/04/2025 at 18:14, 20 hours 48 minutes ago

Résiliation d'une convention conclue entre actionnaires

View all LES ECHOS COMFI WIRE